Neurocognitive impairment (NCI) and treatment engagement (TE) have been shown to significantly predict antiretroviral therapy (ART) adherence, but no studies have explored the ways and the extent to which similar outcomes might occur when these factors operate together, particularly for people who use drugs (PWUDs). We sought to discover whether TE moderated the effect of NCI on adherence to ART in HIV-infected individuals. One hundred sixteen HIV-infected, methadone-maintained people who reported HIV risk behaviors were enrolled in the study. Variables of interest (NCI, ART adherence, TE) were assessed using audio computer-assisted self-interview. Results revealed a significant interactive effect of NCI and TE on ART adherence, which supported the moderation effect. Findings from post hoc analyses showed that NCI was negatively associated with adherence to ART at low levels of TE. Findings suggest the need to accommodate individual NCI and improve TE as a means to enhance ART adherence in HIV-infected PWUDs.
The HIV epidemic continues to be a major global health issue, with approximately 37 million people living with HIV (PLWH) worldwide (Joint United Nations Programme on HIV/AIDS, 2015), and substance use has been closely linked with HIV since the beginning of the epidemic. This link has to do with the increased risk of both contracting and transmitting HIV during drug use and of a worsening of the consequences of HIV infection. People who use drugs (PWUDs) are a critical population for spread of HIV infection, which may occur through behavioral disinhibition, associated with preventable HIV risk behaviors (e.g., inconsistent condom use, sharing of injection equipment; Arasteh, Jarlais, & Perlis, 2008; Marshall et al., 2014; Noar, 2008; Strathdee et al., 2010; Volkow & Montaner, 2011) . Bartlett, DeMasi, Quinn, Moxham, & Rousseau, 2001; Wagner et al., 2011) . PLWH, and particularly PWUDs with HIV infection, are at increased risk of experiencing NCI such that it may significantly impede their abilities to partake fully in treatment services, treatment engagement, and ART adherence (Bates et al., 2006; Fishbein et al., 2007; Shrestha, Huedo-Medina, et al., 2015; Verdejo-Garcia & Perez-Garcia, 2007; Vo et al., 2014) .
Researchers have recognized NCI and treatment engagement as significant predictors of ART adherence (Farrell, Ingersoll, & Ceperich, 2009; Malee et al., 2009; Meade et al., 2011; Nicholas et al., 2014) . Although informative, studies so far have been focused on explaining the independent direct effect of these factors on ART adherence by PLWH. Thus, the possible ways and the extent to which a similar outcome could occur when these factors operate together or interact with each other, particularly for PWUDs, remains an important unanswered question. A better understanding of the extent of the interactive effect (i.e., moderated effect) of NCI and treatment engagement on ART adherence is essential for developing interventions intended to enhance medication adherence in this high-risk population. In our study, we therefore sought evidence about the interactive effect of NCI and treatment engagement on ART adherence in HIV-infected PWUDs in treatment. The hypotheses tested in our study included: (a) NCI will be inversely associated with ART adherence; (b) treatment engagement will be positively associated with ART adherence; and (c) treatment engagement will moderate the effect of NCI on ART adherence. Figure 1 shows the conceptual diagram of the moderated model tested in the study.
Methods
We used data from the Holistic Health for HIV (3H1) project collected from September 2012 to December 2015 to examine the relationships between NCI, treatment engagement, and ART adherence in the study population. The 3H1 project was a randomized controlled trial designed to compare the efficacy of the abbreviated 3H1 intervention (Shrestha, Krishnan, Altice, & Copenhaver, 2015) with the Holistic Health Recovery Program (HHRP1), an existing evidence-based behavioral intervention (Margolin, Avants, Warburton, Hawkins, & Shi, 2003) to reduce HIV-related risk behaviors in HIVinfected drug users in New Haven, Connecticut (Shrestha, Krishnan, et al., 2015) .
The Institutional Review Board at the University of Connecticut and the Human Investigation Committee at Yale University approved the protocol of this study. Additionally, board approval from the APT Foundation Methadone Maintenance Program, Inc. (the research site) was received. Clinical trial registration was completed at www.ClinicalTrials. gov (NCT01741311).
Participants
This study included 116 (male 5 68) HIVinfected, opioid-dependent individuals enrolled in methadone maintenance treatment (MMT) in New Haven, Connecticut. Additional inclusion criteria included: being 18 years of age or older; reporting drug-related (e.g., needle sharing) or sex-related (e.g., inconsistent condom use) HIV risk behavior in the previous 6 months; able to read and understand questionnaires; and not actively suicidal, homicidal, or psychotic.
Measures
Demographic variables. These included participant characteristics including age, gender, ethnicity, education level, marital status, income, methadone dose, and length of drug use history.
Neurocognitive impairment. NCI of the participants was measured using the Brief Inventory of Neurocognitive Impairment (BINI; Copenhaver, Shrestha, Wickersham, Weikum, & Altice, 2016) . The BINI is a brief self-report measure of neuropsychological symptoms, which was developed as a quick and convenient way to help assess diagnostically pertinent information about general and specific cognitive symptoms (e.g., memory, learning, linguistic, academic). The BINI is comprised of 57 items and nine factors that demonstrate excellent overall reliability (a 5 0.97). Factors include: global impairment (e.g., I have difficulty paying attention and I get lost easily); academic-related (e.g., I count with my fingers and I have trouble learning new things); language-related (e.g., My words get mixed up); memory-related (e.g., I have trouble remembering people's names); psychomotor/physical (e.g., I am very clumsy); psychomotor/perceptual (e.g., I have trouble with the left side of my body); anger-related (e.g., I have urges to break and smash things); painassociated (e.g., I have severe headaches); and traumatic head injury-related (e.g., I have been knocked unconscious). The reliability of the nine factors ranged from excellent to good (F1 a 5 0.97 to F9 a 5 0.73). In our study, we used global impairment as a measure of NCI, which included 22 items. The NCI scale was utilized as a continuous variable, with a higher score indicating a greater degree of NCI.
Treatment engagement. As in prior studies, treatment engagement was defined as participants' rates of attendance during the intervention sessions (Gopalan et al., 2010; Lindsey et al., 2014; Littell, Alexander, & Reynolds, 2001). Treatment engagement was assessed by calculating the number of groups attended by participants during the 12 weeks of the intervention period with a range from 1 to 12. Treatment attendance was used as a continuous variable, with higher group attendance indicating greater treatment engagement.
ART adherence. ART adherence was assessed using the empirically validated, self-report visual analog scale (VAS) approach (Giordano, Guzman, Clark, Charlebois, & Bangsberg, 2004) . In this method, participants were asked to indicate the percentage of ART medication taken as directed in the previous month by pointing along a continuous line between 0% and 100%. Higher scores indicated a greater degree of ART adherence.
Procedures
Participants enrolled at the APT Foundation, a community-based MMT facility in New Haven, Connecticut, were screened for participation in the study. Those who met the inclusion criteria of the study were invited to provide informed consent, followed by a baseline assessment. Participants were then randomized to receive (a) the Holistic Health for HIV (3H1) intervention: four weekly group sessions and the 12-week booster session; or (b) the Holistic Health Recovery Program Plus (HHRP1) intervention: 12 weekly group sessions.
Holistic
Health for HIV (3H1). The 3H1 intervention, which included four weekly 60-minute group sessions and a 60-minute booster session at the 12th week, contained only content that related explicitly to drug-or sex-related HIV risk reduction and ART adherence (Copenhaver, Lee, Margolin, Bruce, & Altice, 2011) . 3H1 is a modified coping skills training approach that is delivered in a group setting by two trained intervention facilitators using a motivational enhancement therapeutic style to address high-risk drug-and sexrelated HIV risk behaviors and ART adherence.
Holistic Health Recovery Program Plus (HHRP1). The comparison intervention condition -HHRP1 -has been identified by the Centers for
Disease Control and Prevention as an evidencebased intervention targeting HIV-infected drug users. It is comprised of 12 weekly group sessions with wide-ranging HIV risk reduction content that addresses the medical, social, emotional, and spiritual needs of PLWH. Each session is designed to last 2 hours and is co-facilitated by two trained facilitators (Margolin et al., 2003) .
Participants were assessed at baseline, immediately at postintervention, 3-month follow-up, 6-month follow-up, and 9-month follow-up using audio computer-assisted self-interview (Turner, Rogers, Hendershot, Miller, & Thornberry, 1996) . Everyone enrolled in the study was reimbursed a total of $750 for the time and effort required to participate in all the assessments.
Data Analyses
Data analyses were performed using Statistical Analysis Software (SAS, version 9.4; SAS Institute Inc., Cary, NC) at a 95% confidence interval level (a , .05). We performed Pearson's correlations to identify significant associations for NCI at baseline, treatment engagement during intervention phase, and ART adherence at 9-month follow-up. Outcome data (i.e., ART adherence) was included from the 9-month follow-up because any significant changes that occurred between pre-, post-, and 3-and 6-month follow-ups would tend to weaken the magnitude of influence. This allowed us to examine the influence of NCI on ART adherence over time. We tested our hypotheses in two linked steps. To illustrate, the main effect terms (NCI and treatment engagement) were entered on the first step, and the interaction term (NCI 3 treatment engagement) was entered on the second step, according to the method for determining moderator effects proposed by Baron and Kenny (1986) . All analyses were controlled for gender, income, education status, methadone dose, drug use history, and treatment group. After the moderation test, significant moderators were further analyzed using the post hoc method suggested by Holmbeck (2002) . Two additional regressions were run in which the slope between the independent variable (NCI) and the dependent variable (probability of being ART adherent) was observed when the moderator was re-centered at one standard deviation above and one standard deviation below its mean.
Results

Sample Characteristics
Sociodemographic characteristics of the participants are shown in Table 1 . The mean age of the study sample was 48.8 years (SD 5 8.5), and more than half (58.6%) were male. Thirty-seven percent of the study participants were African American, followed by Hispanic (31.9%), White (29.3%), and others (1.7%). More than half of the participants (52.6%) had never married. Of the total participants, only 15.5% were high school graduates, with the majority earning less than $11,000 USD per year. All participants were enrolled in an inner-city MMT program and were maintained on a stable dose. The mean (6SD) daily methadone dose was 77.9 (631.56) mg. The participants reported using drugs (e.g., opiate, cocaine) regularly for about 22.72 (610.2) years. Table 2 presents the summary statistics and correlations of variables of interest for the participants. The score for NCI ranged from 0 to 162, with a mean score of 63.78 (636.54). Also, the average total score was 6.94 (63.61) for treatment engagement and 91.6 (616.10) for ART adherence. An inspection of the correlations revealed that NCI was significantly and negatively related to ART adherence (r 5 20.305, p 5 .016), whereas treatment engagement was significantly and positively related to ART adherence (r 5 0.321, p 5 .011). Table 3 presents the results of the regression analyses for moderation. As hypothesized, NCI was negatively associated with ART adherence (B 5 2.745, p 5 .004). Treatment engagement was, however, not significantly associated with ART adherence (B 5 2.702, p 5 .468). And finally, an interaction term between NCI and treatment engagement was significantly associated with ART adherence (B 5 .086, p 5 .023). This significant interactive effect supported our third hypothesis of a moderating effect of treatment engagement on the relationship between NCI and ART adherence (Table 3, Figure 2 ). The results of the post hoc analyses showed that NCI had significant negative effect on ART adherence at low levels of treatment engagement (Effect 5 2.4592, p 5 .0033). This effect was, however, nonsignificant at greater levels of treatment engagement. Thus, at a low level of treatment engagement, NCI will be associated with lower levels of ART adherence.
Test of Moderation
Discussion
To our knowledge, our study is the first to assess the influence of NCI, treatment engagement, and the interactive effect of NCI and treatment engagement on ART adherence within the context of HIV-infected PWUDs. Findings here suggest that the relationship between NCI and ART adherence is more complicated than previous studies have indicated (Farrell et al., 2009; Malee et al., 2009; Meade et al., 2011; Nicholas et al., 2014) . Initially, we examined whether NCI would affect ART adherence. We then determined whether treatment engagement would strengthen or weaken the effect of NCI on ART adherence. The results supported the hypothesized moderation model, demonstrating that the magnitude of the effect of NCI on ART adherence was contingent upon an individual's level of engagement in treatment. This result established the preliminary evidence of a previously unexplored domain (i.e., treatment engagement) influencing the impact of NCI on ART adherence for HIV-infected drug users in treatment.
The findings from our study contribute to the existing literature by first reinforcing and then extending prior results. Our results emphasized the impact of NCI, as it showed the main effect on ART adherence. Consistent with previous findings, our study showed the significant effect of the presence and severity of NCI on decreased ART adherence (Cook et al., 2014; Hinkin et al., 2002; Malee et al., 2009; Waldrop-Valverde, Jones, Weiss, Kumar, & Metsch, 2008) . This finding was significant for HIV-infected individuals, particularly PWUDs, who had a greater likelihood of being cognitively impaired, exhibiting depressive symptoms, and having reduced social support due to disease process, lifestyles, and chronic substance use behaviors (Bhatia, Hartman, Kallen, Graham, & Giordano, 2011; Scheyett et al., 2010; Zahari et al., 2010) . As a result, there was an increased likelihood of suboptimal ART adherence through the complex interaction of NCI, depression, and reduced social support.
Moreover, the findings from our study contribute to research on NCI and how it may interact with treatment engagement to impact ART adherence in this high-risk population. As an extension of prior findings, our results showed a moderating effect of treatment engagement on the association between NCI and ART adherence. That is, treatment engagement had a significant impact of NCI on ART adherence, and particularly so for those with lower treatment Our data suggest that cognitive impairment and lower treatment engagement may together be significant predictors of ART adherence for HIV-infected PWUDs. Improving ART adherence may depend on first determining whether cognitive functioning is impaired and then making appropriate accommodations. As such, a systematic assessment of cognitive functioning should be used in routine clinical assessment, and interventions should be tailored to address and take into account the possible effect of NCI in this high-risk population. Ignoring NCI issues will likely result in lower rates of ART adherence.
Additionally, our analyses suggest some interesting directions for future research. For example, we did not assess perceived or available social support, depressive symptoms, or substance use disorders, all of which may impact the influence of NCI on ART adherence. Future studies that expand on the proposed model to include such variables may further contribute to this area of inquiry. Furthermore, future studies need to investigate the moderated model in different study samples to confirm its generalizability.
Limitations
The findings from our study need to be considered in light of a few inherent limitations. First, we utilized self-report assessments, which may have been subject to biases associated with participants' tendencies to misrepresent levels of ART adherence (i.e., over-reporting adherence in VAS scale) and awareness about particular items related to NCI (i.e., underreport NCI on the BINI). This potential bias may have been diminished, however, by the use of audio computer-assisted self-interview, which provided participants with a high level of privacy. Second, the BINI, although a very user-friendly and convenient screening instrument for difficult-toreach populations, was not designed to provide a comprehensive assessment of NCI, and does not measure all possible cognitive domains. Third, the use of the single-item VAS scale to measure participant adherence to ART may not have captured the complex patterns of adherence behavior in HIV-infected individuals. Fourth, our results are specific to HIVinfected drug users in the context of a treatment setting and may not be generalizable to other risk populations in different geographical contexts. Regardless of these limitations, the results of the study have several clinical and research implications and add to our understanding of the processes by which NCI may interact with treatment engagement to affect ART adherence. 
Conclusion
Our findings contribute to a burgeoning literature on NCI as a key factor associated with ART adherence in HIV-infected PWUDs (Farrell et al., 2009; Malee et al., 2009; Meade et al., 2011; Nicholas et al., 2014) . Furthermore, the results provide preliminary evidence of an interaction effect via NCI and treatment engagement, such that NCI has an increased negative effect on ART adherence for individuals with lower treatment engagement. The results of our study, therefore, make a significant contribution to our understanding of the applicability of a moderated model for improving ART adherence by PLWH with some form of cognitive deficit. Given the greater likelihood of cognitive deficits in this high-risk population (Farrell et al., 2009; Malee et al., 2009; Meade et al., 2011; Nicholas et al., 2014) , future interventions seeking to improve ART adherence should include accommodating NCI as a primary goal.
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Key Considerations
Neurocognitive impairment (NCI) and treatment engagement (TE) are significant predictors of antiretroviral therapy (ART) adherence. The results revealed a significant interactive effect of NCI and TE on ART adherence in HIVinfected drug users in treatment. NCI was significantly negatively associated with adherence to ART at low levels of TE. Future interventions seeking to improve ART adherence in HIV-infected drug users in treatment should accommodate individuals' NCI and improve TE.
